Positive Bone Marrow Biopsy Is Associated with a Decreased Disease-Free Survival in Patients with Operable Breast Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Bone marrow (BM) biopsy has been suggested as an independent prognostic factor in patients with breast cancer.
Patients operated for breast cancer from June 2000 to April 2008 were enrolled in this protocol after signing an informed consent. After primary surgery, BM aspirate from the iliac crest was obtained and 5–10 cc of blood collected. Since 2002 a peripheral blood (PB) sample was also obtained. Both carcinoembryonic antigen (CEA) and Mammaglobin-specific nested reverse-transcription polymerase chain reaction (RT-PCR) were used to examine BM and PB samples. Physicians and patients were blinded to results.
Two hundred seventy-three patients underwent BM and/or PB test. The median age of the patients was 63 years (31–80 years), and the median tumor diameter was 1.5 cm (0.1–6 cm). BM aspirates were unsuccessful in nine patients, and RT-PCR was not technically feasible in 18 women, leaving 246 patients available for analysis of results and follow-up. Among them, 110 patients (45%) had either a BM or a PB test positive for CEA or Mammaglobin (Test+). At median follow-up of 60 months, 31 events (deaths or relapse) occurred (13%). Disease-free survival (DFS) was significantly lower in the Test+ group (BP and/or PB) (P < 0.001). This effect was independent of nodal status. At 5 years, event-free survival for Node−/Test− patients was 46/49 (94%) and for Node+/Test+ patients was 21/33 (64%), while patients with only one status positive (Node−/Test+ or Node+/Test−) had an intermediate disease-free survival (35/43, 81%) (P = 0.005). In a subgroup analysis, RT-PCR results for BM and Mammaglobin retained statistical significance on DFS (P < 0.001), while those for PB and CEA did not.
This study confirms that RT-PCR of the BM is an independent prognostic factor for disease-free survival of breast cancer patients, and may improve their staging, allowing better strategies for therapy and follow-up.
- Rosner D, Lane WW. Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res Treat. 1993;25:127–9. CrossRef
- De Vita VT. Breast cancer therapy: Exercising all our options. N Eng J Med. 1997;337:956–62. CrossRef
- Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastatic and circulating tumor cells in solid tumors. Clin Cancer Res. 1999;5:1950–60.
- Janni W, Rack B, Lindemann K, Harbeck N. Detection of micrometastatic disease in bone marrow: Is it ready for prime time? Oncologist. 2005;10:480–92. CrossRef
- Riethdorf S, Wilkman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123:1991–2006.
- Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastases in breast cancer. N Engl J Med. 2005;353:793–802. CrossRef
- Gerhard M, Juhl H, Kalhoff H, Schreiber H, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol. 1994;12:725–9.
- Bostick PJ, Hoon DS, Cote RJ. Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer. N Engl J Med. 1998;339:1643–4.
- Jung YS, Lee KJ, Kim HJ, et al. Clinical significance of bone marrow micrometastasis detected by nested RT-PCR for keratin-19 in breast cancer patients. Jpn J Clin Oncol. 2003;33:167–72. CrossRef
- Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer. 2006;94:672–80.
- Farmen RK, Nordgard O, Gilje B, Shammas FV, Kvaloy JT, Oltedal S, et al. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients. Breast Cancer Res Treat. 2008;108:251–8. CrossRef
- Ooka M, Tamaki Y, Sakita I, et al. Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. Breast Cancer Res Treat. 2001;67:169–75. CrossRef
- Apostolaki S, Perraki M, Kallergi G, et al. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation on their prognostic relevance. Breat Cancer Res Treat. 2008; Nov 19 [Epub ahead of print].
- Fortunato L, Amini M, Costarelli L, Piro FR, Farina M, Vitelli CE. A standardized sentinel lymph node enhanced pathology protocol (SEPP) in patients with breast cancer. J Surg Oncol. 2007;96:470–3. CrossRef
- Muller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res. 2005;11:3678–85. CrossRef
- Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res. 2004;10:1392–400. CrossRef
- Benoy IH, Elst H, Philips M, et al. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clin Breast Cancer. 2006;7:146–52. CrossRef
- Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM, et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer. 2006;118:2013–9. CrossRef
- Ooka M, Sakita I, Fujiwara Y, et al. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep. 2000;7:561–6.
- Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y, Monden M. Mammaglobin B as novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Res Treat. 1999;58:137–40. CrossRef
- Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res. 1996;56:860–5.
- Span PN, Waanders E, Manders P, et al. Mammaglobin is associated with low-grade, steroid receptor–positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol. 2004 22:691–8. CrossRef
- Marchetti A, Buttitta F, Bertacca G, et al. mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. J Pathol. 2001;195:186–90. CrossRef
- Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratine-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002;20:3404–12. CrossRef
- Ismail MS, Wynendaele W, Aerts JL, et al. Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. Clin Cancer Res. 2004;1:196–201. CrossRef
- Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat. 2006;97:91–6. CrossRef
- Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91. CrossRef
- Vlems FA, Ruers TJM, Punt CJA, Wobbes T, van Muijen GNP. Relevance of disseminated tumor cells in blood and bone marrow of patients with solid epithelial tumours in perspective. EJSO. 2003;29:289–302. CrossRef
- Luzzi KJ, MacDonald IC, Schidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153:865–73.
- Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Nat Cancer Inst. 1993;85:1419–24. CrossRef
- Alix-Panabieres C, Vendrell JP, Pelle O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem. 2007;53:537–9. CrossRef
- Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615–21. CrossRef
- Bozionellou V, Mavrouudis D, Perraki M, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res. 2004;10:8185–94. CrossRef
- Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005;103:884–91. CrossRef
- Wiedswang G, Borgen E, Karesen R, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavourable clinical outcome. Clin Cancer Res. 2004;10:5342–8. CrossRef
- Xenidis N, Vlachonikolis I, Mavroudis D, et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol. 2003;14:849–55. CrossRef
- Braun S, Kentenich CR, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J Clin Oncol. 2000;18:80–6.
- Slade MJ, Singh A, Smith BM, et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer. 2005;114:94–100. CrossRef
- Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003;63:5679–84.
- Solomayer EF, Becker S, Pergola-Becker G. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat. 2006;98:179–84. CrossRef
- Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006;12:1715–20. CrossRef
- Benoy IH, Elst H, Van der Auwera I, et al. Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cell in bone marrow aspirates of patients with breast cancer. Br J Cancer. 2004;91:1813–20. CrossRef
- Ring AE, Zabaglo L, Ormerod MG, Smith I.E, Dowsett M. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer. 2005;92:906–12. CrossRef
- Positive Bone Marrow Biopsy Is Associated with a Decreased Disease-Free Survival in Patients with Operable Breast Cancer
Annals of Surgical Oncology
Volume 16, Issue 11 , pp 3010-3019
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, San Giovanni-Addolorata Hospital, Rome, Italy
- 2. Department of Biochemistry, Second University of Naples, Naples, Italy
- 3. Department of Statistical Sciences, University of Padova, Padova, Italy
- 4. Department of Pathology, San Giovanni-Addolorata Hospital, Rome, Italy